Rotshild V - Search Results

1

Calcium Channel Blockers and the Risk for Lung Cancer: A Population-Based Nested Case-Control Study.

Rotshild V, Azoulay L, Feldhamer I, Perlman A, Glazer M, Muszkat M, Matok I. Rotshild V, et al. Ann Pharmacother. 2019 May;53(5):445-452. doi: 10.1177/1060028018814684. Epub 2018 Nov 15. Ann Pharmacother. 2019. PMID: 30442036

2

The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies.

Rotshild V, Azoulay L, Zarifeh M, Masarwa R, Hirsh-Raccah B, Perlman A, Muszkat M, Matok I. Rotshild V, et al. Drug Saf. 2018 Jun;41(6):555-564. doi: 10.1007/s40264-018-0644-4. Drug Saf. 2018. PMID: 29484611 Review.

3

Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides.

Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I. Gorelik E, et al. Among authors: rotshild v. Antimicrob Agents Chemother. 2018 May 25;62(6):e00438-18. doi: 10.1128/AAC.00438-18. Print 2018 Jun. Antimicrob Agents Chemother. 2018. PMID: 29610207 Free PMC article.

4

Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis.

Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Gorelik E, et al. Among authors: rotshild v. Drug Saf. 2019 Apr;42(4):529-538. doi: 10.1007/s40264-018-0751-2. Drug Saf. 2019. PMID: 30368737

5

Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population-Based Nested Case-Control Study.

Rotshild V, Azoulay L, Feldhamer I, Perlman A, Muszkat M, Matok I. Rotshild V, et al. Pharmacotherapy. 2019 Jun;39(6):690-696. doi: 10.1002/phar.2266. Epub 2019 Apr 17. Pharmacotherapy. 2019. PMID: 30917404

6

Reply: "Association Between Lung Cancer and Calcium Channel Blockers Use".

Rotshild V, Perlman A, Matok I. Rotshild V, et al. Ann Pharmacother. 2019 Oct;53(10):1074. doi: 10.1177/1060028019853285. Epub 2019 May 29. Ann Pharmacother. 2019. PMID: 31137953 No abstract available.

7

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression.

Hirsh Raccah B, Yanovsky A, Treves N, Rotshild V, Renoux C, Danenberg H, Eliaz R, Matok I. Hirsh Raccah B, et al. Among authors: rotshild v. Int J Cardiol. 2021 Jul 15;335:7-14. doi: 10.1016/j.ijcard.2021.04.025. Epub 2021 Apr 20. Int J Cardiol. 2021. PMID: 33892045

8

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis.

Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Rotshild V, et al. Sci Rep. 2021 Nov 23;11(1):22777. doi: 10.1038/s41598-021-02321-z. Sci Rep. 2021. PMID: 34815503 Free PMC article.

9

Calcium Channel Blocker Use and the Risk for Breast Cancer: A Population-Based Nested Case-Control Study.

Rotshild V, Hirsh Raccah B, Gazawe M, Matok I. Rotshild V, et al. Cancers (Basel). 2022 May 9;14(9):2344. doi: 10.3390/cancers14092344. Cancers (Basel). 2022. PMID: 35565473 Free PMC article.

10

The Risk for Prostate Cancer With Calcium Channel Blockers: A Systematic Review, Meta-Analysis, and Meta-Regression.

Rotshild V, Rabkin N, Matok I. Rotshild V, et al. Ann Pharmacother. 2023 Jan;57(1):16-28. doi: 10.1177/10600280221098121. Epub 2022 May 28. Ann Pharmacother. 2023. PMID: 35645169

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters